Monopar Therapeutics stock trades near $98.20–$111.48 range as buyer strength dominates session

Traders Union
All News
Financial News
Monopar Therapeutics gains 5.06% today

Highlights

MNPR/USD displays multi-timeframe bullish alignment, supporting continued upward momentum in short, medium, and long-term outlooks.
Momentum indicators remain neutral overall, but intraday buyer dominance and strong finish reinforce the current uptrend.
Price is projected to consolidate between $98.20 and $111.48 with a high probability of further gains and limited downside risk.

Neutral momentum as buyers dominate intraday above support

On the hourly chart, MNPR is trading above the 20-period and 50-period moving averages, with a decisive break above the 200-period moving average on the daily chart. The Ichimoku Kijun on the daily timeframe marks immediate support at $102.91. The Relative Strength Index (RSI) holds at 50.98, suggesting a mild bias to the buy side, while both the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) indicate neutral momentum. Oscillators such as Stochastic RSI and Commodity Channel Index (CCI) also remain neutral. Bull/Bear Power registers a strong buy, highlighting buyer dominance in intraday trade, while the Awesome Oscillator shows a neutral stance.

Upside scenario favored as volatility defines range and risk

Over the coming sessions, MNPR is forecast to trade within a band of $98.20 to $111.48. The high probability scenario favors continued upward movement within this volatility range, with further gains likely if resistance levels are breached. In the less probable bearish outcome, price could retreat below immediate support and test the lower end of the stated range, but momentum indicators suggest the downside risk remains limited for now.

Viktoras Karapetjanc, expert at Traders Union, notes that Monopar Therapeutics is showing clear technical strength in the absence of news catalysts. The stock’s upward momentum is supported by strong positioning above major moving averages and buyer dominance on intraday signals. He sees further gains as likely if resistance levels are breached in the coming sessions. "As long as MNPR holds above support and buyers stay dominant, I expect the uptrend to continue within the projected range."

Earlier, analysts noted that Monopar Therapeutics was exhibiting bullish strength but highlighted emerging downside risks due to stretched market conditions. The current analysis indicates that while upward momentum remains the prevailing scenario, traders should closely monitor for a breach of resistance, which could validate further gains in the near term.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.